Topics

Two Fish-Oil Candidates Fail Late-Stage Tests

08:46 EST 15 Jan 2020 | Medscape

AstraZeneca stops trial of omega-3 carboxylic acids (Epanova) for mixed dyslipidemia; Acasti Pharma trial of omega-3 phospholipid (CaPre) fails to meet end point in severe hypertriglyceridemia.
Medscape Medical News

Original Article: Two Fish-Oil Candidates Fail Late-Stage Tests

NEXT ARTICLE

More From BioPortfolio on "Two Fish-Oil Candidates Fail Late-Stage Tests"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Hyperlipidemia - high cholesterol (hypercholesterolaemia)
Hyperlipidemia involves abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Lipids are transported in a protein capsule, the size of that capsule, or lipoprotein, determines its density. The lipoprotein density and type...